Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Astria Therapeutics, Inc. | a2234670zex-32_1.htm |
EX-32.2 - EX-32.2 - Astria Therapeutics, Inc. | a2234670zex-32_2.htm |
EX-31.2 - EX-31.2 - Astria Therapeutics, Inc. | a2234670zex-31_2.htm |
EX-31.1 - EX-31.1 - Astria Therapeutics, Inc. | a2234670zex-31_1.htm |
10-K - 10-K - Astria Therapeutics, Inc. | a2234670z10-k.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
- 1)
- Registration
Statement (Form S-3 No. 333-212382) of Catabasis Pharmaceuticals, Inc.,
- 2)
- Registration
Statement (Form S-8 No. 333-206394) pertaining to the Amended and Restated 2008 Equity Incentive Plan, as amended, the 2015 Stock Incentive
Plan, and the 2015 Employee Stock Purchase Plan of Catabasis Pharmaceuticals, Inc., and
- 3)
- Registration Statements (Form S-8 No. 333-210229 and Form S-8 No. 333-216793) pertaining to the 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan of Catabasis Pharmaceuticals, Inc.;
of our report dated March 15, 2018, with respect to the consolidated financial statements of Catabasis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Catabasis Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 15, 2018
Consent of Independent Registered Public Accounting Firm